Latest Content

Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.

Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.

Novo Nordisk rebrands as "Novo" under it's "Lasting health starts now" tagline, pairing both with a new cultural framework called "The Novo Way."

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.

Dr. Elena Christofides on why patients who don't respond to diabetes medications deserve a diagnostic workup — not a non-adherence label.

A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

Novartis shareholders share deepened trust issues around the company's dealmaking strategy.

Ten life sciences board directors on AI's three hardest questions: developing the next generation of talent, accountability for speed, and board fluency.

Dr. Elena Christofides on why treatment failure in diabetes should trigger a cortisol screen — not an assumption of non-adherence.

Artisan Partners' David Samra calls for a board shake-up at Novartis after costly deal failures, Kura Oncology spins out Caspian Therapeutics to pursue menin inhibition for diabetes, and Ira Studin examines how payers are redefining unmet need for orphan products.

Why clinical out-of-home marketing has finally become responsive after decades of running static, scheduled messages.